{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:31:28Z","timestamp":1777890688281,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NPM"],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:p>BACKGROUND: Post natal adaptation syndrome is well reported but early presentation of neurological symptoms severe enough to warrant detailed neurological work up is rare. Our aim was to evaluate and describe abnormal early neurological symptoms in infants following in-utero exposure to a varying combination of selective serotonin uptake inhibitor medication and other psychotropic medications, with negative seizure work-up. METHOD: Descriptive case series of infant exposed to selective serotonin uptake inhibitor medication and other psychotropic medications, presenting with early neurologic signs and symptoms within the first 24 hours of life concerning for seizures, who underwent an extensive neurologic evaluation. RESULTS: Five infants met criteria. Infant #1\u200a:\u200a39-weeks gestational age (GA), with escitalopram, clonazepam, gabapentin, methadone exposure, presented with generalized hypertonia and intermittent back-arching. #2\u200a:\u200a40-weeks GA with escitalopram and hydroxyzine exposure, with bilateral arm stiffening and sucking mouth movements. #3\u200a:\u200a34-weeks GA with fluoxetine, quetiapine and clonazepam exposure, presented with decerebrate posturing. #4\u200a:\u200a38-weeks GA with fluoxetine, clonazepam, clonidine, quetiapine and gabapentin exposure, presented with asynchronous tremoring of all extremities. #5\u200a:\u200a35-weeks GA with citalopram, quetiapine exposure, presented with increased tone and posturing of upper extremities. Electroencephalogram was negative for seizures in all infants. CONCLUSION: In-utero exposure to selective serotonin uptake inhibitor medication, especially in combination with other psychotropic medications, may be associated with significant abnormal neurological symptoms, which may not represent true seizures.<\/jats:p>","DOI":"10.3233\/npm-230165","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T12:51:07Z","timestamp":1721739067000},"page":"717-722","source":"Crossref","is-referenced-by-count":2,"title":["Non epileptiform abnormal neurologic signs in newborns following in-utero psychotropic medication exposure"],"prefix":"10.1177","volume":"17","author":[{"given":"Ruben","family":"Vaidya","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabeel","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salima","family":"Kakshapati","sequence":"additional","affiliation":[{"name":"Department of Medicine, National Academy of Medical Sciences, Kathmandu, Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijen","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Beachy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"5","key":"10.3233\/NPM-230165_ref1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.semperi.2008.08.001","article-title":"Fetal and neonatal effects of maternal drug treatment for depression","volume":"32","author":"Belik","year":"2008","journal-title":"Semin Perinatol"},{"issue":"7","key":"10.3233\/NPM-230165_ref2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5694\/j.1326-5377.2007.tb00940.x","article-title":"Maternal mortality and psychiatric morbidity in the perinatal period: challenges and opportunities for prevention in the Australian setting","volume":"186","author":"Austin","year":"2007","journal-title":"Med J Aust"},{"issue":"3","key":"10.3233\/NPM-230165_ref3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.genhosppsych.2012.12.010","article-title":"National trends in antidepressant medication treatment among publicly insured pregnant women","volume":"35","author":"Huybrechts","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"issue":"2","key":"10.3233\/NPM-230165_ref4","doi-asserted-by":"crossref","first-page":"194.e1","DOI":"10.1016\/j.ajog.2007.07.036","article-title":"Use of antidepressant medications during pregnancy: A multisite study","volume":"198","author":"Andrade","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"10.3233\/NPM-230165_ref5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1542\/pir.2017-0201","article-title":"Effect of maternal substance abuse on the fetus, neonate, and child","volume":"39","author":"Bailey","year":"2018","journal-title":"Pediatr Rev"},{"issue":"2","key":"10.3233\/NPM-230165_ref6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejpn.2016.11.003","article-title":"Neonatal venlafaxine discontinuation syndrome: A mini-review","volume":"21","author":"Holland","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"10.3233\/NPM-230165_ref7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpedi.160.2.173","article-title":"Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants","volume":"160","author":"Levinson-Castiel","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.3233\/NPM-230165_ref8","doi-asserted-by":"crossref","unstructured":"Brajcich MR , Palau MA , Messer RD , Murphy ME , Marks J . Why the maternal medication list matters: Neonatal toxicity from combined serotonergic exposures. Pediatrics. 2021;147(2).","DOI":"10.1542\/peds.2019-2250"},{"issue":"4","key":"10.3233\/NPM-230165_ref9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/JCP.0b013e318295fe12","article-title":"Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study","volume":"33","author":"Habermann","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.3233\/NPM-230165_ref10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3109\/01443615.2014.991292","article-title":"Poor neonatal adaptation following in-utero exposure to quetiapine and lamotrigine","volume":"35","author":"Lau","year":"2015","journal-title":"J Obstet Gynaecol"},{"issue":"1","key":"10.3233\/NPM-230165_ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408449209145319","article-title":"The human hepatic cytochromes P450 involved in drug metabolism","volume":"22","author":"Wrighton","year":"1992","journal-title":"Crit Rev Toxicol"},{"issue":"4","key":"10.3233\/NPM-230165_ref12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.spen.2010.10.002","article-title":"Developmental pharmacokinetics","volume":"17","author":"Anderson","year":"2010","journal-title":"Semin Pediatr Neurol"},{"issue":"2","key":"10.3233\/NPM-230165_ref13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.3233\/NPM-230165_ref14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","article-title":"Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: A retrospective study based on 2,087 patients","volume":"175","author":"Juki\u0107","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.3233\/NPM-230165_ref15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0028-1103296","article-title":"Placental transfer of SSRI and SNRI antidepressants and effects on the neonate","volume":"42","author":"Rampono","year":"2009","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.3233\/NPM-230165_ref16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40262-014-0233-3","article-title":"Placental transfer of antidepressant medications: Implications for postnatal adaptation syndrome","volume":"54","author":"Ewing","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.3233\/NPM-230165_ref17","first-page":"262","article-title":"Developmental pharmacokinetics in pediatric populations","volume":"19","author":"Lu","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"10.3233\/NPM-230165_ref18","doi-asserted-by":"crossref","first-page":"19921","DOI":"10.1038\/s41598-020-77106-x","article-title":"New insights into quetiapine metabolism using molecular networking","volume":"10","author":"Le Dar\u00e9","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"10.3233\/NPM-230165_ref19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/17425255.2013.759209","article-title":"Understanding the pharmacokinetics of anxiolytic drugs","volume":"9","author":"Altamura","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.3233\/NPM-230165_ref20","doi-asserted-by":"crossref","unstructured":"T\u00f3th K , Csukly G , Sirok D , Belic A , Kiss \u00c1 , H\u00e1fra E , et al. Optimization of clonazepam therapy adjusted to patient\u2019s CYP3A status and NAT2 genotype. Int J Neuropsychopharmacol. 2016;19(12).","DOI":"10.1093\/ijnp\/pyw083"},{"issue":"2","key":"10.3233\/NPM-230165_ref21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cpdd.326","article-title":"Current concepts in methadone metabolism and transport","volume":"6","author":"Kharasch","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"10.3233\/NPM-230165_ref22","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1542\/peds.2011-3212","article-title":"Neonatal drug withdrawal","volume":"129","author":"Hudak","year":"2012","journal-title":"Pediatrics"},{"issue":"2","key":"10.3233\/NPM-230165_ref23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1542\/peds.48.2.178","article-title":"Neonatal narcotic addiction: 10 year observation","volume":"48","author":"Zelson","year":"1971","journal-title":"Pediatrics"},{"issue":"1","key":"10.3233\/NPM-230165_ref24","first-page":"58","article-title":"Late presentation of drug withdrawal symptoms in newborns","volume":"127","author":"Kandall","year":"1974","journal-title":"Am J Dis Child"}],"container-title":["Journal of Neonatal-Perinatal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/NPM-230165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:43:41Z","timestamp":1777614221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/NPM-230165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":24,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.3233\/npm-230165","relation":{},"ISSN":["1934-5798","1878-4429"],"issn-type":[{"value":"1934-5798","type":"print"},{"value":"1878-4429","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}